Crawford Nomination Clears OIG Hurdle To Face Committee Vote, Plan B Hold
This article was originally published in The Tan Sheet
Executive Summary
The conclusion of the HHS Inspector General's investigation into allegations against FDA Commissioner nominee Lester Crawford likely will bring the agency's delay of the Plan B emergency contraceptive switch application back into the foreground
You may also be interested in...
Commissioner Von Eschenbach: NCI Director Named Acting Head Of FDA
National Cancer Institute Director Andrew von Eschenbach, MD, brings extensive scientific expertise and experience working with Congress as the head of a high-profile federal agency to the role of FDA commissioner
Commissioner Von Eschenbach: NCI Director Named Acting Head Of FDA
National Cancer Institute Director Andrew von Eschenbach, MD, brings extensive scientific expertise and experience working with Congress as the head of a high-profile federal agency to the role of FDA commissioner
Commissioner Von Eschenbach: NCI Director Named Acting Head Of FDA
National Cancer Institute Director Andrew von Eschenbach, MD, brings extensive scientific expertise and experience working with Congress as the head of a high-profile federal agency to the role of FDA commissioner